Response Rate with Cetuximab Used Less Than 3 Months after Immunotherapy (IO) for Recurrent/metastatic Head and Neck Squamous Cell Carcinomas (R/M HNSCC) Compared to Larger Delay.
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要